v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Disclosure Text Block [Abstract]  
Segment Information

14. Segment Information

The Company’s performance is reported in one segment. During 2026, there have been no changes to the Company’s basis of segmentation or in the basis of measurement of segment loss.

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net product revenue

 

$

42,805

 

 

$

100,779

 

 

$

79,055

 

 

$

187,472

 

Grant income

 

 

950

 

 

 

226

 

 

 

1,928

 

 

 

226

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

23,673

 

 

 

27,630

 

 

 

49,445

 

 

 

51,353

 

Clinical expense

 

 

8,737

 

 

 

3,954

 

 

 

13,799

 

 

 

7,981

 

Sales and marketing

 

 

31,038

 

 

 

48,941

 

 

 

69,134

 

 

 

96,974

 

General and administrative

 

 

22,497

 

 

 

24,028

 

 

 

43,879

 

 

 

47,662

 

Other segment items (a)

 

 

54,077

 

 

 

5,844

 

 

 

54,149

 

 

 

11,963

 

Segment net loss

 

 

(96,267

)

 

 

(9,392

)

 

 

(149,423

)

 

 

(28,235

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment net loss:

 

 

 

 

 

 

 

 

 

 

 

 

Reconciling items

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Consolidated net loss

 

$

(96,267

)

 

$

(9,392

)

 

$

(149,423

)

 

$

(28,235

)

(a) Other segment items include: research and development related severance, salary, payroll taxes and benefits, research and development related rent and other facilities expense, research and development related depreciation and amortization, write-down to fair value for asset held for sale other income, net, and income tax benefit (expense).